Results 21 to 30 of about 11,074 (164)

Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis [PDF]

BMC Cancer
Objectives To identify optimal treatments and sequencing strategies that maximize efficacy, safety, and net health benefits (NHB, a comprehensive measure of safety and efficacy) for ALK-positive non-small-cell lung-cancer (NSCLC).
Mingye Zhao, Jiaqi Li, Yunlin Jiang, Hanqiao Shao, Jin Huang, Wenxi Tang   +5 more
doaj   +2 more sources

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

JTO Clinical and Research Reports
Introduction: Central nervous system (CNS) metastases remain a common challenge in patients with ALK-positive NSCLC. We previously reported reinduction of CNS responses using dose-intensified alectinib in two patients with CNS progression on standard ...
Justin M. Cheung, MD, Jiyoon Kang, DO, Beow Y. Yeap, ScD, Jennifer L. Peterson, BS, Andrew Do, BS, Justin F. Gainor, MD, Subba R. Digumarthy, MD, Jessica J. Lin, MD   +7 more
doaj   +2 more sources

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

Case Reports in Oncology, 2021
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib.
Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, Shoichi Kuyama   +4 more
doaj   +1 more source

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

Cancer Reports, 2021
Background Most patients treated with anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitors for ALK‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous system (CNS) being a ...
Hiroaki Sakamoto, Noriko Yanagitani, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Sadatomo Tasaka, Makoto Nishio   +12 more
doaj   +1 more source

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report

Journal of Medical Case Reports, 2022
Background Targeted therapy with anaplastic lymphoma kinase inhibitor alectinib has become standard therapy for selected patients with non-small cell lung carcinoma. Few data are available on the renal effects of alectinib.
Marco van Londen, Elizabeth Roosma, Stefanie Vogels, John W. G. van Putten, Wilbert M. T. Janssen   +4 more
doaj   +1 more source

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

JTO Clinical and Research Reports, 2023
Introduction: Alectinib was found to have superior efficacy to crizotinib in the phase 3 ALEX study and is a preferred initial treatment for patients with advanced ALK-positive NSCLC. To understand the efficacy of alectinib in U.S.
Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD   +9 more
doaj   +1 more source

Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling

Clinical and Translational Science, 2023
Alectinib, approved as 150 mg capsules for the treatment of adults with advanced ALK‐positive non‐small cell lung cancer, is being assessed in children with ALK‐positive solid and central nervous system tumors.
Stephanie N. Liu, Priya Agarwal, Katja Heinig, Asim Datye, Carolina Sturm‐Pellanda, Andrea Crugnola, Marc Arca, Dale Miles   +7 more
doaj   +1 more source

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer

Diagnostics, 2022
Companion diagnostic tests and targeted therapy changed the management of non-small cell lung cancer by diagnosing genetic modifications and enabling individualized treatment.
Sulim Kang, Jaehyun Woo, Sungmin Kim
doaj   +1 more source

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

, 2023
OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lym-phoma kinase mutation-positive nonsmall cell lung carcinoma.
Nuran Katgı, Pınar Gürsoy, Aguloglu, Nursin, Gursoy, Pinar, Katgı, Nuran, Pinar Cimen, Katgi, Nuran, Akyol, Murat, Pınar Çimen, Gürsoy, Pınar, Murat Akyol, Nursin Aguloglu, Cimen, Pinar, Nuran Katgi, Pinar Gursoy, Çimen, Pınar   +15 more
core   +1 more source

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Frontiers in Oncology, 2023
ObjectiveDespite the promising efficacy and tolerability of alectinib in treating advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), the role of alectinib in neoadjuvant setting remains understudied in ALK-rearranged ...
Liang Shi, Shuhong Gao, Li Tong, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, Zhe Liu   +7 more
doaj   +1 more source